PPARA and fatty liver disease: Pioglitazone is classified as a weak ligand for PPARα, and as such reduces insulin resistance, suppresses inflammation, and infers a role in increasing β-oxidation [15]; whilst improving hepatic steatosis and non-alcoholic fatty liver disease [16].